-naive and refractory), NSCLC (I st-line and pre-treated), and head and neck cancer. Further, we expect pembro to be the first PD-1 to launch (post- Yervoy melanoma, admittedly small indication) with a PDUFA in October. • Merck confirms PD-I efficacy in IL PD-L1+ NSCLC with 47% irRC ORIL First data fro

gy agents have nearly doubled in the past decade, from an average of $5000 per month to more than $10,000 per month. The price for cancer drugs like Yervoy, Opdivo and Keytruda routinely exceeds $120,000 a year. Some other specialty drugs have even higher prices. Cerezyme for Gaucher disease costs abou